Korea's IMBDx Explores NSCLC Therapy Guidance, Multi-Cancer Early Detection for Liquid Biopsy Tech

IMBDx, a Korean cancer diagnostics company, is advancing its AlphaLiquid liquid biopsy technology for various applications,

including lung cancer therapy guidance and multi-cancer early detection (MCED).

The company's AlphaLiquid platform, which includes assays for tumor profiling, recurrence monitoring,

and minimal residual disease detection, aims to improve cancer care.

Their flagship AlphaLiquid 100 detects cancer-related mutations in plasma and pleural effusion samples, showing clinical utility in non-small cell lung cancer (NSCLC).

IMBDx is also expanding its platform for use with other sample types, such as cerebrospinal fluid (CSF), 

and stepping into the MCED space with CancerFind, which screens for eight cancer types. 

The company is working to expand CancerFind to detect 30 cancers by 2029 

through a project funded by Korea's ARPA-H, aiming for Korean FDA approval and global commercialization. 

They are also collaborating with AstraZeneca on liquid biopsy diagnostics for targeted therapies in prostate cancer and other cancers. 

IMBDx's efforts focus on integrating liquid biopsies into clinical guidelines to improve cancer care and outcomes.

[Publications]

Enhanced Detection of Actionable Mutations in NSCLC Through Pleural Effusion Cell-Free DNA Sequencing: A Prospective Study

Clinical utility and predictive value of cerebrospinal fluid cell-free DNA profiling in non-small cell lung cancer patients with leptomeningeal metastasis

Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer

Full Article